Key Companies in the Neurostimulation Devices Market

Why Neurostimulation Devices Market Is Expanding?

The Global Neurostimulation Devices Market is on a robust growth trajectory, rising from USD 9.98 billion in 2025 to a projected USD 29.72 billion by 2035, at a CAGR of 11.50% over the 2026–2035 forecast period. Market Research Future (MRFR) identifies three co-equal primary demand engines: the accelerating global burden of neurological disease — the World Health Organization reports roughly 55 million dementia patients worldwide as of 2022, with nearly 10 million new cases diagnosed annually — the technological shift from open-loop to closed-loop, AI-enabled implantable pulse generator systems, and expanded reimbursement coverage for neuromodulation treatment procedures across North America and Europe.

The convergence of rising chronic pain prevalence, aging demographics, and digital health infrastructure investment provides self-reinforcing structural tailwinds that sustain above-baseline growth well through the 2035 forecast horizon.

Approximately one in five persons worldwide suffer from chronic pain, according to the International Association for the Study of Pain, and opioid-alternative treatments are increasingly preferred by regulators. The American Society of Anesthesiologists' new clinical guidelines place peripheral nerve stimulation and spinal cord stimulator therapy as front-line neuromodulation treatment options, thereby increasing the number of patients that can be treated.

While external devices are growing at a CAGR of 13.2% through 2035, driven by non-invasive vagus nerve and transcranial stimulation platforms gaining regulatory clearance across multiple regions, implantable devices hold approximately 64% of the market share due to the strong demand for rechargeable implantable pulse generator platforms.

What Structurally Separates Leaders from the Field?

Four structural factors are identified by MRFR as defining category leadership in the Neurostimulation Devices Market: regulatory scale and multi-continent approval density; technology investment in closed-loop sensing algorithms and directional lead architectures; integrated neuromodulation portfolio breadth encompassing spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and responsive neurostimulation; and disciplined M&A strategy to acquire complementary neurostimulation assets that increase indication coverage and geographic reach.

With the largest implantable pulse generator portfolio in the world thanks to its SenSight directional lead system and Percept PC platform, Medtronic's market leadership is defined by its integrated portfolio breadth. Boston Scientific, which has FDA approvals and CE marking for pain, mobility disorders, and urological neuromodulation indications, stands out on the regulatory scale. The competitive path of Nevro and NeuroPace, which have both used AI-powered adaptive stimulation algorithms to distinguish clinical outcomes, is determined by their technological investment. The competitive position of Boston Scientific, which finished acquiring Axonics in 2024 to expand its urology line with sacral neuromodulation equipment, has been changed by M&A-driven consolidation.

Top 10 Global Neurostimulation Devices Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading neurostimulation devices companies globally, evaluated on the basis of revenue performance, geographic presence, product breadth, technology strategy, innovation investment, and patient population served. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of June 2026.

Detailed Company Profiles

Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic's neuromodulation division generated USD 1.17 billion in FY2024 revenue within the company's USD 32.4 billion total consolidated revenue (SEC 10-K, FY2024). The company's decision to vertically integrate closed-loop sensing technology — rather than rely on third-party algorithm providers — is a technology pre-emption that competitors dependent on external partnerships cannot replicate within a product cycle.

Medtronic's SenSight directional lead system enables precision targeting that replaces broad-field stimulation, while the Percept PC platform (FDA approved June 2020) integrates brain-responsive sensing with adaptive output adjustment using BrainSense technology. With 150+ country presence and the broadest implantable pulse generator portfolio spanning spinal cord stimulation, deep brain stimulation, and sacral nerve stimulation, Medtronic holds an installed base advantage that creates switching costs for hospitals and academic medical centers.

Boston Scientific Corp. | NYSE: BSX | Marlborough, Massachusetts, USA

Boston Scientific's neuromodulation segment delivered USD 1.11 billion in FY2024 revenue, representing year-over-year growth and 6.6% of consolidated net sales (SEC 10-K, FY2024). The company's acquisition of Axonics in 2024 for approximately USD 3.7 billion added sacral neuromodulation systems for urinary and bowel dysfunction, filling a capability gap that competitors Medtronic and Abbott had already addressed.

The Relievant Medsystems acquisition (November 2023, USD 850 million upfront) added the FDA-cleared Intracept intraosseous nerve ablation system for vertebrogenic pain. Boston Scientific's WaveWriter Alpha spinal cord stimulator platform and Vercise deep brain stimulation system are positioned as closed-loop therapy leaders. The company's FY2024 R&D investment of USD 1.6 billion — 9.6% of net sales — funds neuromodulation algorithm development.

Abbott Laboratories | NYSE: ABT | Abbott Park, Illinois, USA

Abbott reported USD 41.95 billion in total company revenue for FY2024 (SEC 10-K, FY2024). The company's Medical Devices segment, which includes neuromodulation alongside cardiovascular, diabetes care, and electrophysiology, generated USD 18.99 billion. Abbott does not separately disclose neuromodulation segment revenue in standalone form. The company's BurstDR stimulation technology — which delivers intermittent burst patterns rather than tonic stimulation — is a waveform differentiation that has demonstrated superior pain relief in head-to-head clinical trials against conventional spinal cord stimulator therapy.

Abbott's Proclaim XR platform offers extended battery life, reducing revision surgery frequency. The Infinity deep brain stimulation system integrates with Abbott's proprietary directional lead architecture. Abbott acquired Bigfoot Biomedical in September 2023 (terms undisclosed) to expand connected diabetes management solutions.

Nevro Corp. (Globus Medical) | NASDAQ: NVRO (delisted April 2025) | Redwood City, California, USA

Nevro reported USD 408.5 million in FY2024 revenue, a 3.9% decrease year-over-year, reflecting competitive pressure in the spinal cord stimulation market (SEC filings, FY2024). The company's HFX iQ system with AdaptivAI represents a pivot from hardware-centric to algorithm-centric differentiation, using artificial intelligence to optimize 10 kHz high-frequency stimulation parameters in real time.

Globus Medical completed its acquisition of Nevro on April 3, 2025, for approximately USD 250 million in an all-cash transaction at USD 5.85 per share — a 27% premium over the 90-day weighted average. Nevro common stock ceased trading on the NYSE prior to market open on April 3, 2025. The HFX iQ CE Mark certification enables European expansion, though international revenue remains a small fraction of the total.

LivaNova plc | NASDAQ: LIVN | London, United Kingdom

LivaNova's neuromodulation segment generated USD 554.2 million in FY2024 revenue, representing 6.6% year-over-year constant-currency growth within the company's USD 1.25 billion total revenue (SEC 10-K, FY2024). The company's VNS Therapy System holds a dominant market position in vagus nerve stimulation for epilepsy.

LivaNova's RECOVER clinical study data for treatment-resistant depression demonstrated clinically meaningful therapeutic effects versus sham, potentially expanding the addressable market beyond epilepsy into psychiatric indications. The OSPREY study for obstructive sleep apnea met primary safety and efficacy endpoints, opening a third indication vertical. LivaNova's geographic concentration in the US and Europe limits exposure to Asia-Pacific growth, but also insulates it from emerging market reimbursement volatility.

ElectroCore Inc. | NASDAQ: ECOR | Rockaway, New Jersey, USA

ElectroCore reported record FY2024 revenue of USD 25.2 million, a 57% increase over FY2023, driven by 85% growth in prescription gammaCore sales through the US Department of Veterans Affairs and Department of Defense channels (SEC filings, FY2024). The company's gammaCore Sapphire non-invasive vagus nerve stimulation device received European commercialization clearance, positioning it as a prescription-grade home-use neuromodulation treatment pioneer.

ElectroCore's Truvaga wellness handset grew 174% in FY2024, indicating consumer-market appetite for non-invasive neurostimulation outside traditional medical device channels. With USD 12.2 million in cash and a reduced net loss of USD 11.9 million (down 37% YoY), the company is approaching operational breakeven.

NeuroPace Inc. | NASDAQ: NPCE | Mountain View, California, USA

NeuroPace reported USD 79.9 million in FY2024 revenue, a 22% increase over FY2023, driven by increased RNS System sales at Comprehensive Epilepsy Centers (SEC filings, FY2024). The company's Responsive Neurostimulation (RNS) System is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source — a closed-loop architecture.

NeuroPace's Project CARE initiative expands site-of-service beyond academic centers, while the NAUTILUS trial for idiopathic generalized epilepsy remains on track to complete one-year patient follow-up visits in March 2025, with FDA submission planned in the second half of 2025. With 73.9% gross margin in FY2024 and decreasing cash burn, NeuroPace strengthened its balance sheet through a February 2025 public offering with net proceeds of approximately USD 20.2 million.

Axonics Inc. (Boston Scientific) | NASDAQ: AXNX (delisted post-acquisition) | Irvine, California, USA

Axonics reported nine-month 2024 revenue of USD 322.2 million (25.5% YoY growth) before its acquisition by Boston Scientific closed in 2024 (SEC filings, Q3 2024). The company's sacral neuromodulation systems for overactive bladder and fecal incontinence held the #2 market position behind Medtronic's InterStim platform, with Axonics' rechargeable device offering a 15+ year lifespan that reduced replacement surgery burden.

The Bulkamid urethral bulking agent for stress urinary incontinence added a non-implantable revenue stream. Boston Scientific's acquisition, valued at approximately USD 3.7 billion (USD 71 per share), integrated Axonics into its urology portfolio, creating cross-selling opportunities with the company's existing endoscopy and urology device salesforce.

Synapse Biomedical | Private | Oberlin, Ohio, USA

Synapse Biomedical is a private company commercializing the NeuRx Diaphragm Pacing System (DPS), developed over two decades at Case Western Reserve University and University Hospitals of Cleveland. The device provides electrical stimulation for chronic respiratory insufficiency in spinal cord injury and ALS patients — a neuromodulation niche that large device manufacturers have ceded due to small addressable populations.

Synapse operates as a specialized respiratory neuromodulation provider rather than a broad neurostimulation platform competitor. The company's technology addresses diaphragm conditioning in muscular dystrophies and short-term intensive care respiratory support. As a private company, Synapse does not publicly disclose audited financial statements.

Bioventus Inc. | NASDAQ: BVS | Durham, North Carolina, USA

Bioventus reported USD 573.3 million in FY2024 revenue, an 11.9% increase over the prior year, driven by double-digit growth in its Pain Treatments and Surgical Solutions segments (SEC filings, FY2024). While Bioventus is primarily known for bone growth stimulation and active healing technologies, its portfolio includes adjacent neuromodulation applications that position it as a peripheral player in the broader neurostimulation ecosystem.

The company's FY2024 adjusted EBITDA from continuing operations of USD 108.9 million reflects operational discipline following the divestiture of its Advanced Rehabilitation Business. Bioventus' focus on outpatient-compatible pain management devices aligns with the shift toward non-invasive and minimally invasive neuromodulation treatment alternatives.

M&A Activity Tracker (2022–2025)

The Neurostimulation Devices Market has experienced targeted consolidation as large medtech operators pursued inorganic growth to capture converging pain management, movement disorder, and urology neuromodulation markets — with Boston Scientific's acquisition of Axonics representing the most significant transaction in reshaping competitive positioning. Market Research Future tracks the following verified, named transactions directly relevant to the neurostimulation devices market.

Key Trend: MRFR analysis identifies vertical integration of neuromodulation into broad medtech platforms as a dominant M&A theme. Boston Scientific's Axonics acquisition created the only company with meaningful presence across spinal cord stimulation, deep brain stimulation, and sacral neuromodulation — a portfolio breadth that rivals Medtronic's historical dominance.

R&D Investment & Innovation Signals

• Medtronic continues to integrate closed-loop sensing across its neuromodulation portfolio following the Percept PC platform launch (FDA approved June 2020), connecting brain-responsive algorithms with its population health analytics infrastructure to generate predictive risk alerts for patients at elevated disease progression risk — a data moat that competitors without equivalent installed base cannot replicate.
• Boston Scientific's FY2024 R&D investment of USD 1.6 billion funds neuromodulation algorithm development and the Axonics integration, with the company building the broadest interventional chronic pain portfolio spanning spinal cord stimulation, radiofrequency ablation, and sacral neuromodulation.
• Nevro's HFX iQ system with AdaptivAI represents a pivot from hardware-centric to algorithm-centric differentiation, using artificial intelligence to optimize 10 kHz high-frequency stimulation parameters in real time — though the Globus Medical acquisition raises questions about whether the AI platform will receive continued standalone investment under orthopedic spine ownership.
• NeuroPace's NAUTILUS trial for idiopathic generalized epilepsy remains on track for FDA submission in the second half of 2025, with one-year patient follow-up visits completing in March 2025 — a regulatory catalyst that could validate responsive neurostimulation for a significantly larger patient population.